Cyclosporine alone vs cyclosporine plus methotrexate for post-transplant immunosuppression after HLA-identical sibling bone marrow transplantation: A randomized prospective study

Bone Marrow Transplantation

Volumn 34, Issue 7, 2004, Pages 627-636

  Lee, K H ^a   Choi, S J ^a   Lee, J H ^a,a   Kim, S ^a   Seol, M ^a   Lee, Y S ^a   Kim, W K ^a   Lee, J S ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Cyclosporine; HLA identical sibling BMT; Methotrexate; Post transplant immunosuppression

Indexed keywords

ACICLOVIR; BUSULFAN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GANCICLOVIR; HEPARIN; IMMUNOGLOBULIN; MESNA; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMORRHAGIC CYSTITIS; HEPATITIS; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION;

ACUTE DISEASE; ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, CHRONIC; MALE; METHOTREXATE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; RECURRENCE; SIBLINGS; SURVIVAL RATE; TISSUE DONORS;

EID: 5044249076     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704624     Document Type: Article

References (32)

1. Lazarus HM, Coccia PF, Herzig RH et al. Incidence of acute graft-versus-host disease with and without methotrexate prophylaxis in allogeneic bone marrow transplant patients. Blood 1984; 64: 215-220.
2. Powles RL, Clink HM, Spence D et al. Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation. Lancet 1980; 1: 327-329.
3. Chao NJ, Schmidt GM, Niland JC et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329: 1225-1230.
4. Deeg HJ, Storb R, Thomas ED et al. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 1985; 65: 1325-1334.
5. Storb R, Deeg HJ, Fisher L et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trails. Blood 1988; 71: 293-298.
6. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
7. Storb R, Pepe M, Deeg HJ et al. Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Blood 1992; 80: 560-561.
8. Storb R, Deeg HJ, Farewell V et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986; 68: 119-125.
9. Storb R, Deeg HJ, Pepe M et al. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anemia: long-term follow-up of a controlled trial. Br J Haematol 1989; 72: 567-572.
10. Storb R, Leisenring W, Deeg HJ et al. Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine vs methotrexate alone in patients given marrow grafts for severe aplastic anemia. Blood 1994; 83: 2749-2750.
11. Mrsiæ M, Labar B, Bogdaniæ V et al. Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 1990; 6: 137-141.
12. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Bone Marrow Transplant 1997; 19: 759-764.
13. Bacigalupo A, Tedone E, Isaza A et al. CMV-antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigen positive cell numbers with transplant-related mortality. Bone Marrow Transplant 1965; 16: 155-161.
14. Aschan J, Ringdén O, Sundberg B et al. Methotrexate combined with cyclosporine A decreases graft-versus-host disease, but increases leukemia relapse compared to monotherapy. Bone Marrow Transplant 1991; 7: 113-119.
15. Lee J-H, Lee K-H, Lee J-H et al. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide. Br J Haematol 2002; 118: 1087-1094.
16. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
17. Sullivan KM. Acute and chronic graft-versus-host disease in man. Int J Cell Cloning 1986; 4 (Suppl. 1): 42-93.
18. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
19. Lee K-H, Lee J-H, Choi S-J et al. Monthly prospective analysis of hematopoietic chimerism after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2003; 32: 423-431.
20. Zikos P, Van Lint MT, Frassoni F et al. Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: a randomized study of low-dose cyclosporin vs low-dose cyclosporin and low-dose methotrexate. Blood 1998; 91: 3503-3508.
21. Locatelli F, Zecca M, Rondelli R et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood 2000; 95: 1572-1579.
22. Locatelli F, Bruno B, Zecca M et al. Cyclosporin A and short-term methotrexate vs cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 2000; 96: 1690-1697.
23. van Marwijk Kooy M, van Prooijen HC, Moes M et al. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood 1991; 77: 201-205.
24. Lee K-H, Lee J-H, Choi SJ et al. Randomized comparison of two different schedules of granulocyte colony-stimulating factor administration after allogeneic bone marrow, transplantation. Bone Marrow Transplant 1999; 24: 591-599.
25. Bacigalupo A, Van Lint MT, Occhini D et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423-1428.
26. Choi S-J, Lee K-H, Lee J-H et al. Peri-engraftment clinical abnormalities following allogeneic hematopoietic cell transplantation: a retrospective review of 216 patients. Bone Marrow Transplant 2003; 32: 809-813.
27. Morishima Y, Morishita Y, Tanimoto M et al. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. Blood 1989; 74: 2252-2256.
28. Atkinson K, Horowitz MM, Gale RP et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459-2464.
29. Weiden PL, Sullivan KM, Flournoy N et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529-1533.
30. Sullivan KM, Weiden PL, Storb R et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720-1728.
31. Brunet S, Urbano-Ispizua A, Ojeda E et al. Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies. Br J Haematol 2001; 114: 544-550.
32. Socié G, Clift RA, Blaise D et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001; 98: 3569-3574.